The company specializes in designer recombinant nucleosomes that contain defined post-translational modifications, develops assays for chromatin-modifying enzymes and PTM-binding proteins using a variety of readouts and employing nucleosome or peptide-based substrates, enabling researchers all over the world to avail technology to do research. EpiCypher is a pioneer in the field of epigenetics and chromatin biology, offering transformative technologies and superior products to researchers worldwide. Their renowned chromatin researchers possess unique insight and expertise in chromatin biology and drug discovery, which benefits customers in ways other companies cannot. Epigenetics is an emerging area of biomedical research with broad impact on human health and disease, and EpiCypher's technologies and products are making studies possible that were not imaginable just a few years ago.